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Antimicrobial Therapy for Acute Colonic Diverticulitis
Matthew C. Byrnes* and John E. Mazuski
Abstract
Background: Although guidelines and reviews have systematically evaluated diagnosis and surgical manage-
ment of acute diverticulitis, they have focused only minimally on antibiotic selection for the treatment of this
disease. We undertook a review of the literature to assess more clearly the use of specific antimicrobial agents
in the treatment of patients with acute diverticulitis of the colon.
Methods: A MEDLINE search was conducted to identify original research, review papers, and guidelines on
the use of antimicrobial agents for the treatment of acute diverticulitis.
Results: The general recommendation to use antibiotics with activity against common gram-negative and anaer-
obic pathogens has remained consistent. A number of single agents and combination regimens provide such
activity. However, there is little evidence on which to base selection of specific antimicrobial regimens, and no
regimen has demonstrated superiority. In general, episodes of diverticulitis severe enough to warrant hospi-
talization should be managed initially with intravenous antibiotics. Oral therapy can be used for outpatient
treatment or when the patient’s condition improves. There is a paucity of data regarding the optimal duration
of antimicrobial therapy.
Conclusions: Careful clinical studies are needed to evaluate better the antibiotic regimens for the treatment of
acute diverticulitis. Until such studies are conducted, we are forced to rely on tradition, in vitro analyses, phar-
macokinetic profiling, and indirect evidence from studies of complicated intra-abdominal infections to deter-
mine appropriate therapy for this disease.
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OVER THE PAST TWO DECADES, substantial advances havebeen made in the management of acute colonic diver-
ticulitis. Improved diagnosis and staging have been facili-
tated by modern imaging techniques, particularly computed
tomography (CT). The ability to temporize the acute disease
through medical therapy alone has been extended by ad-
vances in interventional radiology (e.g., percutaneous
drainage). Concomitantly, the indications for surgical inter-
vention have been narrowed and defined more clearly, de-
creasing the need for emergency procedures.
During this period, numerous antimicrobial agents have
been developed and marketed. Their use has been studied
carefully for the management of many infectious diseases.
However, even though antimicrobial therapy is integral to
the management of acute diverticulitis, there is remarkably
little clinical evidence regarding the optimal approach to
such therapy. The general recommendation of providing
coverage of gram-negative and obligate anaerobic bacteria
has remained consistent [1–3], but recommendations re-
garding specific antimicrobial regimens have not been well
delineated.
A number of important questions should be considered
with regard to antimicrobial therapy for acute diverticulitis:
1. Among the many antibiotics available to treat this dis-
ease, is any single agent or combination regimen supe-
rior?
2. What is the appropriate duration of antimicrobial therapy
when treating diverticulitis?
3. When should an antibiotic regimen be altered?
4. What clinical conditions or patient risk factors (e.g., age
or disease severity) might prompt a change in the general
approach to the provision of antibiotics for this disease?
Although guidelines and reviews have addressed diag-
nostic and surgical management of this disease process, they
have not evaluated the aforementioned questions systemat-
ically [1–4]. In fact, no review has focused specifically on the
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selection of antibiotics for the treatment of acute diverticuli-
tis. We reviewed the literature to define more clearly the use
of antimicrobial agents in treating this disease.
Overview
The incidence of colonic diverticular disease increased in
the Twentieth Century, in part because of lifestyle changes
[5,6]. This disease process is a significant cause of morbidity
and death in developed countries. The incidence is closely re-
lated to age: Diverticulosis can be found in 30% of the popu-
lation aged 60 years or older, and in 60% of the population
aged 80 years or older [4]. As the population continues to age,
the prevalence of diverticular disease is likely to increase.
Pathophysiology
Diverticular disease is an acquired phenomenon, seen pri-
marily in populations consuming a low-fiber diet, such as
that of the United States [6]. Chronic elevation of intralumi-
nal pressure leads to outpouching of the colonic mucosa
[1,7]. This results in the formation of pseudodiverticula,
which are composed only of the inner layer of the bowel
wall. Diverticula tend to form near the vasa recta, which are
sites of intrinsic weakness [8].
As many as 25% of persons with diverticulosis ultimately
develop an infectious complication [9,10]. The inciting event
leading to an episode of diverticulitis is believed to be ob-
struction of the diverticular neck, analogous to the patho-
physiology of appendicitis. The diverticular mucosa contin-
ues to secrete mucus, which leads to distention of the
diverticulum until it becomes ischemic and perforates. This
colonic perforation is suspected to be a component of nearly
all cases of clinically manifest diverticulitis. The opening may
range from a microperforation to gross fecal spillage [11].
Clinical presentation
The hallmark of acute diverticulitis is left lower quadrant
abdominal pain. Evacuation patterns are variable, and blood
in the stool is uncommon [4,12,13]. Patients typically are
febrile and anorexic. Laboratory abnormalities, such as
leukocytosis, are consistent with an infectious etiology. Com-
puted tomography and, to a lesser extent, sonography are
used most widely for diagnosis and staging of the disease.
Diverticulitis can present as uncomplicated or complicated
disease. The latter is characterized by overt perforation, ob-
struction, abscess formation, or fistulization. As the severity
of the episode increases, patients typically develop more dif-
fuse abdominal pain. Septic shock ensues occasionally. Ap-
proximately one-third of patients will experience a recur-
rence after an initial acute episode.
Clinical staging
The extent of perforation associated with diverticulitis has
been described by the Hinchey classification [12,14]:
I. Localized perforation with a pericolonic phlegmon. This
perforation typically is contained by the mesocolon or
epiploic appendages;
II. Perforation with abscess formation;
III. Perforation with purulent peritonitis;
IV. Free perforation with feculent peritonitis.
There also is a subset of patients with radiographic evi-
dence of mild colonic thickening and inflammatory changes
in the surrounding fat who have no evidence of a pericolonic
phlegmon. This condition sometimes is described as Hinchey
class “0.” However, a Hinchey classification of “0” also has
been used to describe patients who have not had diagnostic
imaging, so this nomenclature is not precise.
The Hinchey classification has been used to stratify pa-
tients for operative vs. nonoperative therapy. In general, pa-
tients with Hinchey class 0 and I disease are treated nonop-
eratively initially, whereas patients with Hinchey III and IV
disease typically undergo early operative intervention. Pa-
tients with Hinchey II disease can be temporized with anti-
biotics alone, percutaneous drainage, or operative interven-
tion, with percutaneous drainage being selected most
commonly as the initial measure. Regardless of the decision
made with respect to source control, nearly all patients re-
ceive antimicrobial therapy.
Microbiology of Diverticulitis
The selection of appropriate antimicrobial agents for the
treatment of diverticulitis should be based on an under-
standing of the microbiology of the disease process. Because
diverticular infections originate from colonic perforations
[1], the offending bacteria are components of the normal
colonic flora, including anaerobic, gram-positive, and gram-
negative organisms. Anaerobic bacteria outnumber aerobic
and facultative organisms on the order of 1,000:1, with Bac-
teroides fragilis being the most common. The microbial load
of stool is high, with 1010–1011 bacteria present per gram [15].
The microbiology of diverticulitis likely resembles that of
other complicated intra-abdominal infections, which has
been studied extensively. Intra-abdominal infections are
characterized by bacterial growth in a normally sterile site
in the abdominal cavity, usually resulting from a perforation
of the gastrointestinal tract. Complicated intra-abdominal in-
fections are those treated with a surgical procedure or per-
cutaneous drainage. The usual finding is a polymicrobial in-
fection, with an average of five organisms identified per
patient [16,17]. Escherichia coli and B. fragilis are the faculta-
tively aerobic and anaerobic species isolated most com-
monly.
Although the microbiology of complicated intra-abdomi-
nal infection may be a reasonable surrogate for that of di-
verticulitis, certain points need to be borne in mind. Com-
plicated intra-abdominal infections result from many types
of gastrointestinal perforations, not just the colonic perfora-
tions pathognomonic of diverticulitis. Moreover, in most
studies of complicated intra-abdominal infections, many of
the microbiologic specimens are obtained from patients with
perforated appendicitis, who usually are much younger than
patients with diverticular disease. Some change in the bac-
terial flora of the lower gastrointestinal tract attributable to
aging cannot be excluded. Finally, these specimens are by
definition obtained from patients who undergo a source con-
trol procedure; the microbiological results from these more
disseminated infections may not be identical to those of ear-
lier, more localized infections typical of diverticulitis man-
aged nonoperatively. Thus, the microbiology of acute diver-
ticulitis could differ to some extent from that observed with
complicated intra-abdominal infections.
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Brook et al. specifically evaluated patients with peritoni-
tis related to diverticulitis [18]. One hundred ten patients
with diffuse peritonitis and 27 patients with abdominal ab-
scesses secondary to diverticulitis were studied over a 15-
year period. About three-quarters of the specimens were
polymicrobial, with an average of three species of bacteria
isolated per patient. E. coli was cultured from 71% of pa-
tients. A sizable minority of patients (10–20%) were infected
with gram-positive organisms. The most common of these
were streptococci. About 10% of patients were infected with
group D streptococci (likely Enterococcus spp.). Bacterioides
fragilis was isolated from one-half of the clinical specimens.
In addition to Bacteroides spp., the most common anaerobic
bacteria were Clostridium spp. and Fusobacterium spp. These
results provide reassurance that the microbiology of com-
plicated diverticulitis resembles that of complicated intra-ab-
dominal infection.
Complicated intra-abdominal infections can be character-
ized as community-acquired or hospital-acquired [19]. Hos-
pital-acquired infections tend to be associated with more re-
sistant organisms, such as Pseudomonas spp., Enterobacter
spp., Enterococcus spp., and staphylococci. Patients with di-
verticulitis in whom initial medical management has failed
may have infections caused by these more resistant organ-
isms, because typically, they have received broad-spectrum
antibiotics that select for such pathogens.
Antimicrobial Therapy for Acute Diverticulitis
As a general principle, an antimicrobial regimen for any
disease process should have: 1) Activity against the offend-
ing bacteria; 2) minimal toxicity; 3) good penetration into the
tissues being treated; and 4) clinical efficacy. This fourth
point is of the greatest importance, as there are many ex-
amples of antibiotic regimens that are active in vitro, but fail
in clinical trials. Conversely, there are regimens that do not
appear to have adequate in vitro activity against certain bac-
teria, yet have demonstrated clinical efficacy. With polymi-
crobial infections such as intra-abdominal infections, some
microorganisms, such as enterococci, demonstrate limited
pathogenicity. Provided the antimicrobial regimen reduces
the burden of the major pathogens, in this case, gram-nega-
tive bacilli and anaerobes, the host defenses suffice to erad-
icate less pathogenic organisms.
For diverticulitis, many antimicrobial agents satisfy the
first three requirements (Tables 1 and 2). However, there is
relatively little information regarding the clinical efficacy of
these regimens. In fact, although antimicrobial therapy gen-
erally is considered essential for the management of diver-
ticulitis, even this point can be disputed. One retrospective
study reported a 96% success rate in treating patients using
restriction of oral intake only without antibiotics [20]. How-
ever, illness was mild, and it is unclear if these results are
applicable to most patients with this disorder. Most authors,
including those who have written guidelines, recommend
antimicrobial therapy for the treatment of acute diverticuli-
tis; it would not be prudent to withhold antibiotics from pa-
tients who show systemic signs of illness, such as fever or
leukocytosis, in the absence of a well-designed prospective
trial demonstrating the efficacy of this approach and identi-
fying any subsets of patients from whom antimicrobial ther-
apy could be withheld safely.
Our literature review revealed only one randomized con-
trolled trial of different antimicrobial regimens specifically
for the treatment of acute diverticulitis. In 1992, Kellum et
al. reported clinical success rates of 90% and 86% for patients
with acute diverticulitis randomized to receive cefoxitin
alone or gentamicin  clindamycin, respectively (p  0.05)
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aNot recommended by some authorities because of increased re-
sistance of Bacteroides fragilis.
bFood and Drug Administration approved for intra-abdominal in-
fections.
cNot recommended as first-line therapy because of increased resis-
tance of community-acquired Escherichia coli.
dAccording to product labeling, FDA approved specifically for ap-
pendicitis and peritonitis.
TABLE 2. COMBINATION REGIMENS FOR ACUTE DIVERTICULITIS
Aminoglycosidea  an anti-anaerobic agentb
Tobramycinc
Gentamicind





Monobactam  an anti-anaerobic agentb
Aztreonamc
Trimethoprin/sulfamethoxazolee  an anti-anaerobic agentb
Fluoroquinolone  an anti-anaerobic agentb
Ciprofloxacinf
Levofloxacine
aNot recommended as first-line therapy because of toxicity con-
cerns.
bMetronidazole or clindamycin have been used as anti-anaerobic
agents. Many authorities question the utility of clindamycin because
of increasing resistance of Bacteroides fragilis and the association of
the drug with Clostridium difficile colitis.
cFood and Drug Administration approved for intra-abdominal in-
fections; combination agents not mentioned in the product labeling.
dFDA approved for peritonitis; combination agents not mentioned
in the product labeling.
eNot FDA approved for inta-abdominal infections.
fFDA approved for inta-abdominal infections when administered
with metronidazole.
[21]. Otherwise, there are few class I data (i.e., data derived
from adequately powered, randomized controlled trials) on
which to base recommendations with regard to antimicro-
bial therapy of diverticulitis. As such, it is necessary to rely
on indirect clinical evidence to develop recommendations.
Such evidence comes from various clinical trials of anti-
microbial efficacy in the treatment of patients with compli-
cated intra-abdominal infections, and from in vitro data doc-
umenting the susceptibilities of common pathogens to
various antimicrobial agents.
On the basis of the microbiology of complicated intra-
abdominal infections and diverticulitis and the available
clinical data on the treatment of these disorders, the use of
antimicrobial regimens with activity against various gram-
negative, gram-positive, and anaerobic pathogens has be-
come standard practice. Mixed combinations of facultative
aerobic and anaerobic microorganisms exhibit synergistic
growth, so failure to cover one microorganism may lead to
persistence of the infection [22]. Both animal and clinical
studies have demonstrated higher failure and mortality rates
when antibiotic coverage is inadequate [23,24]. In particular,
anaerobic coverage appears to be essential, although there
are no large prospective trials examining omission of anaer-
obic coverage for patients with diverticulitis or complicated
intra-abdominal infection. Nearly all regimens that have ac-
tivity against the usual gram-negative organisms found in
these infections also cover the common anaerobic strepto-
cocci involved in this disease process; thus, the need for such
coverage is rarely a consideration by itself. However, the
need for enterococcal coverage is a much more controversial
issue, which is considered later.
Published Guidelines
A number of guidelines and review papers have described
generally accepted approaches to the diagnosis and man-
agement of acute diverticulitis. The American Society of Col-
orectal Surgeons and the American College of Gastroen-
terology have published recommendations on this topic [2,3].
Neither of these guidelines focuses solely on antibiotic se-
lection. The limitation of all guidelines and reviews is that
there is little high-quality clinical evidence on which to base
recommendations. Thus, the sections of these guidelines that
describe antibiotic selection generally rely on expert opinion
and refer to review papers rather than to original studies as
their justifications. There is an implicit assumption that reg-
imens with similar in vitro activity will have equivalent ther-
apeutic efficacy.
The American Society of Colon and Rectal Surgeons
guidelines on practice parameters for diverticulitis were
published in 2000 and subsequently revised in 2006 [2,25].
These guidelines recommend selecting antibiotics “to treat
the most common bacteria found in the colon: Gram-nega-
tive rods and anaerobes.” The guidelines also indicate that
“single and multi-antibiotic regimens are equally effective.”
Although this point has been supported by numerous review
papers, the conclusion actually is based on the single study
described earlier, which compared gentamicin  clin-
damycin with cefoxitin [21]. It is unknown if this conclusion
holds true for regimens in more common use today.
The American College of Gastroenterology guidelines on
the diagnosis and treatment of diverticular disease were pub-
lished in 1999 [3]. The recommended antimicrobial regimens
included cefoxitin or ampicillin/sulbactam as single agents,
and an aminoglycoside, third-generation cephalosporin, or
monobactam in combination with an anti-anaerobic agent as
combination regimens. The guidelines indicated that these
regimens were “based more on clinical consensus than on
randomized trials.”
A more extensive body of evidence was available for the
development of guidelines on the use of antibiotics for pa-
tients with complicated intra-abdominal infection. The ma-
jor guidelines were created by the Surgical Infection Society
(SIS) in 2002 and by the Infectious Diseases Society of Amer-
ica (IDSA) in 2003 [19,26]. The IDSA guidelines recommend
ampicillin/sulbactam, ticarcillin/clavulanic acid, or er-
tapenem as monotherapy and cefuroxime, cefazolin, or a flu-
oroquinolone with metronidazole as combination therapy
for mild-to-moderate complicated intra-abdominal infec-
tions. They recommend piperacillin/tazobactam, imipenem/
cilastatin, or meropenem as monotherapy and a third- or
fourth-generation cephalosporin, ciprofloxacin, or aztre-
onam with metronidazole as combination therapy for more
severe intra-abdominal infections.
The guidelines for antimicrobial therapy of complicated
intra-abdominal infections pertain indirectly to the treatment
of most patients with diverticulitis. They are applicable
specifically only to those patients who undergo operative
procedures or percutaneous drainage. Even in this patient
group, it is unclear if the guidelines are entirely appropriate.
The studies of antimicrobial therapy for complicated intra-
abdominal infections generally have been performed in pa-
tients with a heterogeneous group of infections, including
those developing after perforations of the appendix, gastro-
duodenal ulcers, and various lesions of the small and large
bowel. In nearly all these studies, the most frequent diag-
nosis has been perforated appendicitis. Diverticulitis patients
have constituted a minority of those enrolled in most trials.
Aside from the source of infection, a fundamental differ-
ence between treatment of diverticulitis and that of compli-
cated intra-abdominal infections is that most patients with
diverticulitis are managed nonoperatively initially, whereas
patients with complicated intra-abdominal infections are re-
quired to have undergone a source control procedure. Thus,
in patients with complicated intra-abdominal infections, the
role of antibiotics is primarily as an adjunct to source con-
trol, whereas in most patients with diverticulitis, there is
complete reliance on the antimicrobial regimen and the host
response to eradicate the infection. In actuality, treatment of
nonoperatively managed intra-abdominal infections, such as
diverticulitis, may be a more rigorous test of antimicrobial
efficacy than is treatment of the usual complicated intra-ab-
dominal infection, in which a source control procedure elim-
inates most of the microbial inoculum.
Specific Regimens
Aminoglycosides
Aminoglycoside antibiotics were used extensively in the
past to treat complicated intra-abdominal infections. They
have broad gram-negative and some gram-positive cover-
age; however, because they have no appreciable anti-anaer-
obic activity, they are combined with an anti-anaerobic agent
when treating intra-abdominal infections. Several aminogly-
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cosides are available, including gentamicin, tobramycin,
netilmicin, and amikacin, with gentamicin being the most
commonly used agent in the class. Aminoglycosides are bac-
tericidal and exhibit concentration-dependent killing. Once-
daily dosing is as efficacious as traditional dosing, and po-
tentially associated with less nephrotoxicity [27]; this
approach has not been validated thoroughly with respect to
intra-abdominal infections, however. Aminoglycosides dis-
tribute into the extracellular fluid but have questionable tis-
sue penetration. In individual trials, aminoglycoside-based
regimens appeared to have efficacy similar to that of other
antimicrobials for the treatment of complicated intra-ab-
dominal infections [28–31]. However, a recent meta-analysis
suggested that aminoglycoside-based regimens were inferior
to other agents for this indication [32]. Moreover, given the
nephrotoxicity and ototoxicity of these agents, many clini-
cians now view this class of antibiotics as a second-line op-
tion for the treatment of complicated intra-abdominal infec-
tions [33].
These considerations likely apply to the treatment of pa-
tients with diverticulitis. Although results of the randomized
trial [21] suggest that these drugs can be used for this indi-
cation, their toxicity and poor tissue penetration probably
should relegate them to second-line therapy. Their require-
ments for intravenous administration and pharmacokinetic
monitoring make them a poor choice for outpatient use.
Cephalosporins
There are at least 25 cephalosporins available for clinical
use; they are grouped into four “generations” with different
spectra of activity. Although the general rule is increasing
gram-negative activity and decreasing gram-positive activ-
ity with increasing generation, this rule is inexact. First-gen-
eration cephalosporins are used primarily for gram-positive
coverage, although they have activity against many of the
common Enterobacteriaceae in complicated intra-abdominal
infections, such as E. coli and Klebsiella. Second-generation
cephalosporins are more difficult to characterize. Some, such
as cefoxitin, have anti-anaerobic activity, whereas others,
such as cefuroxime, have a wider spectrum of gram-nega-
tive coverage but little anti-anaerobic activity. Third-gener-
ation cephalosporins have better gram-negative coverage,
heterogeneous gram-positive coverage, and unreliable
anaerobic coverage. The fourth-generation cephalosporin,
cefepime, has broad gram-positive and gram-negative cov-
erage, but lacks activity against Bacteroides spp.
These agents are bactericidal and act by inhibiting cell wall
synthesis, leading to bacterial lysis. Pharmacokinetic profiles
differ, but all cephalosporins achieve good concentrations in
peritoneal fluid. Adverse effects are uncommon and include
allergic reactions and, rarely, anaphylaxis. However, pseudo-
membranous colitis caused by Clostridium difficile is a con-
cern with the use of these agents.
Cefoxitin is the primary second-generation cephalosporin
with anti-anaerobic activity that is available for monother-
apy of complicated intra-abdominal infections [34,35]. In
older trials, cefoxitin performed similarly to other compara-
tors in the treatment of these infections. For treatment of di-
verticulitis, cefoxitin was tested directly against an amino-
glycoside-based regimen in a randomized trial, and
appeared to be therapeutically equivalent [21]. However,
concern has been raised about its efficacy because of in-
creasing in vitro resistance of anaerobic bacteria, particularly
B. fragilis, to the agent [19]. The clinical significance of this
finding remains unclear.
Multiple studies have evaluated the use of third- or fourth-
generation cephalosporins in combination with an anti-
anaerobic agent for the treatment of complicated intra-ab-
dominal infections. Clinical success rates have been 75–100%
[36,37]. These regimens appear to be superior to aminogly-
coside-based regimens [32], and have performed similarly to
other comparators.
Penicillin/beta-lactamase inhibitor combinations
Three intravenous penicillin/beta-lactamase inhibitor
combinations were recommended in the SIS and IDSA guide-
lines for use in patients with complicated intra-abdominal
infections: ampicillin/sulbactam, ticarcillin/clavulanic acid,
and piperacillin/tazobactam. In addition, an oral formula-
tion, amoxicillin/clavulanic acid, was recommended for con-
tinuation of antimicrobial therapy. All of these agents have
activity against gram-positive, gram-negative, and anaero-
bic bacteria. With regard to gram-negative bacteria, ampi-
cillin/sulbactam has the narrowest spectrum of activity and
piperacillin/tazobactam the broadest. Ticarcillin/clavulanic
acid lacks activity against Enterococcus faecalis, whereas the
other agents typically cover this microorganism. These anti-
biotics distribute well into most tissues as well as the peri-
toneal fluid. They are bactericidal and act by inhibiting cell
wall synthesis, leading to bacterial lysis. There is a low inci-
dence of adverse effects; potential side effects include ana-
phylaxis, other allergic reactions, pseudomembranous coli-
tis, and thrombocytopenia.
The intravenous penicillin/beta-lactamase inhibitor combi-
nations generally have shown good efficacy when used as
monotherapy for complicated intra-abdominal infections. Re-
cently, however, the use of ampicillin/sulbactam has come un-
der scrutiny [19]. In older clinical trials, this agent appeared to
perform similarly to comparators, with success rates of 86–89%
[23,38]. However, a recent study of bacterial isolates from pa-
tients with intra-abdominal infections in 40 countries demon-
strated a 45% rate of resistance of E. coli to ampicillin/sulbac-
tam [39]. In another recent study, Krobot et al. identified
“inappropriate” antimicrobial therapy as a risk factor for treat-
ment failure in patients with community-acquired intra-ab-
dominal infections; a significant proportion of this “inappro-
priate” therapy was attributable to resistant E. coli [40].
Accordingly, unless local resistance patterns demonstrate bet-
ter susceptibility profiles, ampicillin/sulbactam probably
should not be considered a first-line agent for intra-abdominal
infections. Ticarcillin/clavulanic acid appeared to be equiva-
lent to comparator regimens in clinical trials, with success rates
of approximately 88% in complicated intra-abdominal infec-
tions [41]. Piperacillin/tazobactam is one of the agents used
most extensively for complicated intra-abdominal infections.
It performed similarly to imipenem/cilastatin, ciprofloxacin 
metronidazole, various cephalosporins  metronidazole, and
ertapenem in clinical trials [42–44].
Carbapenems
Four carbapenem agents are approved for use in the
United States: imipenem/cilastatin, meropenem, doripenem,
ANTIMICROBIAL AGENTS FOR DIVERTICULITIS 147
and ertapenem. Imipenem/cilastatin and meropenem gen-
erally are considered to have the broadest spectra of any anti-
microbial agents, with activity against gram-positive, gram-
negative, and anaerobic organisms. Doripenem was recently
approved by the FDA for treatment of complicated intra-ab-
dominal infections and has a similar broad spectrum of ac-
tivity. Ertapenem has a somewhat narrower range of activ-
ity, with coverage of many gram-positive, gram-negative,
and anaerobic organisms but limited activity against
Pseudomonas, Acinetobacter, and Enterococcus. Because of its
long half-life, once-daily dosing can be used for patients with
complicated intra-abdominal infections. Carbapenems have
good tissue penetration and distribute well into peritoneal
fluid. They inhibit cell wall synthesis and are bactericidal.
Adverse effects are uncommon and include seizures
(imipenem/cilastatin), anaphylaxis, pseudomembranous
colitis, and agranulocytosis.
Many prospective trials have evaluated carbapenems
against other classes of antibiotics as well as against each
other for the treatment of complicated intra-abdominal in-
fections. Success rates have ranged from 70–100% and gen-
erally have been similar to those of comparators [31,45–47].
Monobactams
Aztreonam is the only antibiotic in the monobactam class
that has been released by regulatory authorities. It is a syn-
thetic beta-lactam antibiotic for intravenous administration
only. It is bactericidal and acts by inhibiting cell wall syn-
thesis. It penetrates most body tissues well; high concentra-
tions are found in peritoneal fluid. It is highly active against
most gram-negative organisms but has no significant gram-
positive or anaerobic activity. Accordingly, it must be used
with an anti-anaerobic agent when treating intra-abdominal
infections. In addition, given the lack of gram-positive cov-
erage, there is a theoretical concern about inadequate strep-
tococcal activity if it is used in combination with metron-
idazole instead of clindamycin. There is a low incidence of
adverse effects with this agent; possible effects are anaphy-
laxis, toxic epidermal necrolysis, and pseudomembranous
colitis. Of note, most patients with penicillin allergies can be
treated safely with this agent. A theoretical problem with
aztreonam is that it induces beta-lactamase production;
when exposed to this agent, bacteria may begin expressing
the enzyme, which could make ultimate eradication of the
infection more difficult [48].
Several prospective trials have evaluated aztreonam 
clindamycin against either gentamicin  clindamycin or
imipenem/cilastatin for complicated abdominal infections
[30,49,50]. The success rate of aztreonam  clindamycin was
71–100%. No significant differences were noted between this
regimen and the comparators.
Trimethoprim/sulfamethoxazole
Trimethoprim/sulfamethoxazole is a sulfa drug combina-
tion with activity against some gram-positive and gram-neg-
ative organisms, including most Enterobacteriaceae. It lacks
enterococcal and pseudomonal coverage. It is bactericidal
and acts by inhibiting sequential enzymes required for folic
acid synthesis. It distributes well into most body tissues and
peritoneal fluid. Hypersensitivity reactions are somewhat
more common with this class of drugs than with various an-
tibiotics; Stevens-Johnson syndrome is an uncommon but
devastating complication.
Trimethoprim/sulfamethoxazole lacks anti-anaerobic ac-
tivity, so it must be combined with metronidazole when
treating intra-abdominal infections. It has been suggested as
a treatment for diverticulitis [47], particularly as it can be ad-
ministered orally. It also is indicated for certain forms of en-
terocolitis. Although its spectrum of action seems appropri-
ate for intra-abdominal infections, one international study
indicated that only 69% of urinary isolates of E. coli were, in
fact, susceptible to this drug combination in vitro [51]. Thus,
the utility of this regimen in the treatment of patients with
diverticulitis remains unclear.
Tetracyclines and glycylcyclines
Tetracyclines have not been tested extensively for the
treatment of complicated intra-abdominal infections, al-
though they were used in the past for these infections. The
recent release of tigecycline has led to renewed interest in
these agents for this indication. Tigecycline is a glycylcycline
that has a broad spectrum of activity against anaerobic bac-
teria and many resistant gram-positive and gram-negative
organisms, with the exception of Pseudomonas. Tigecycline
proved to be non-inferior to imipenem/cilastatin in prospec-
tive trials in patients with complicated intra-abdominal in-
fections, and it has been approved for this indication [52]. It
is concentrated actively in tissues, including the colon. Given
its spectrum of activity and tissue concentration, it likely
would be useful for the treatment of acute diverticulitis.
However, because no oral formulation is available, tigecy-
cline is not a good choice for outpatient therapy.
Fluoroquinolones
Two fluoroquinolone agents currently in use have been
evaluated formally and approved for the treatment of pa-
tients with complicated intra-abdominal infections: Cipro-
floxacin (in combination with metronidazole) and moxi-
floxacin (as monotherapy). Fluoroquinolones are bactericidal
and act by inhibiting DNA gyrase. They exhibit concentra-
tion-dependent killing and have a prolonged post-antibiotic
effect. They are distributed widely in tissues and achieve
higher concentrations in intraperitoneal organs than in
serum. They are available in oral and parenteral formula-
tions. Ciprofloxacin has broad gram-negative activity, lim-
ited gram-positive activity, and no anti-anaerobic activity.
Accordingly, it is used with metronidazole when treating in-
tra-abdominal infections. Moxifloxacin has activity against
common gram-positive, gram-negative, and anaerobic or-
ganisms, and thus can be used as monotherapy for compli-
cated intra-abdominal infections. Moxifloxacin has less ac-
tivity against resistant gram-negative organisms, such as
Pseudomonas, and probably is suited better to community-ac-
quired than nosocomial intra-abdominal infections.
Several clinical trials have compared the use of cipro-
floxacin  metronidazole with other agents for complicated
abdominal infections [43,53–55]. Success rates have been
74–97%, similar to those of comparator regimens. One of
these trials prospectively evaluated a change to oral formu-
lations of ciprofloxacin  metronidazole after initial intra-
venous therapy with these agents, and concluded that such
a switch could be made without sacrifice of efficacy.
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Ciprofloxacin  metronidazole probably has become the
regimen used most commonly for the management of acute
diverticulitis, especially in the outpatient setting.
Levofloxacin, in combination with metronidazole, has
been prescribed widely for the treatment of complicated in-
tra-abdominal infections, as well as for the treatment of acute
diverticulitis. However, levofloxacin has not been approved
in the United States for the treatment of complicated intra-
abdominal infections. Because levofloxacin and ciprofloxacin
have similar activities against enteric gram-negative organ-
isms, it generally has been assumed that levofloxacin 
metronidazole would be equivalent to ciprofloxacin 
metronidazole for this indication, but no published studies
have verified this assumption. The optimal dosing of lev-
ofloxacin for complicated intra-abdominal infection or di-
verticulitis is not known.
Moxifloxacin was evaluated recently for complicated in-
tra-abdominal infections in a randomized controlled trial
[56]. Intravenous moxifloxacin with an option for oral con-
version was compared with piperacillin/tazobactam, with
the option of conversion to oral amoxicillin/clavulanic acid.
About 15% of the patients had perforations of the large or
small bowel. The clinical cure rates were similar in the two
groups. No studies have evaluated the efficacy of moxi-
floxacin specifically for the treatment of diverticulitis. In
view of the clinical efficacy of ciprofloxacin  metronida-
zole, the antibacterial profile of moxifloxacin, and its con-
centration in target tissues [57], it probably is suitable for this
indication. Potential advantages of moxifloxacin for acute di-
verticulitis include the availability of an oral formulation, the
option of using this agent as monotherapy, its once-daily
dosing, and the absence of a need for dosing adjustments for
renal failure [58].
The side effect profiles of fluoroquinolones generally are
favorable, with relatively few severe adverse reactions. How-
ever, the potential association of fluoroquinolone use with
epidemics of C. difficile–associated disease has been the sub-
ject of several recent reports [59-64]. In the past, C. diffi-
cile–associated disease was linked epidemiologically to a va-
riety of antibiotics, including clindamycin, cephalosporins,
and ampicillin and ampicillin/sulbactam. Thus, it is difficult
to ascertain the clinical importance of these findings. In fact,
a recent study of epidemic C. difficile–associated disease in
Québec found no association with the use of any specific an-
tibiotic [65]. Careful attention to infection control practices
rather than arbitrary changes in antibiotic prescribing prac-
tices was believed to be the most important measure in de-
creasing the spread of this pathogen.
Anti-anaerobic agents
It generally is accepted that antibiotic regimens aimed at
treating diverticulitis should include anaerobic coverage
when the gram-negative agents lack intrinsic activity against
anaerobes. Regimens with inadequate anaerobic coverage
have been associated consistently with higher failure rates
in patients with complicated intra-abdominal infections. The
two agents that have been used most often to provide sup-
plemental anti-anaerobic coverage are clindamycin and
metronidazole. Traditionally, these agents were considered
equally efficacious, a concept supported by data from older
prospective trials. However, more recent in vitro data have
demonstrated increasing resistance of B. fragilis and other
anaerobic bacteria to clindamycin [66,67]. Although there
have been no studies demonstrating that these changes in
resistance have led to poorer clinical outcomes, this possi-
bility remains a concern for some practitioners. In addition,
the association of clindamycin with C. difficile colitis has led
some to shy away from its use in intra-abdominal infections.
Currently, most authorities reserve this antibiotic for situa-
tions in which metronidazole should not or cannot be used.
Single agent and combination regimens that can be consid-
ered for the treatment of acute diverticulitis are listed in Ta-
bles 1 and 2, respectively.
Treatment of Higher Risk Patients
Certain clinical considerations relevant to the manage-
ment of higher risk patients with complicated intra-abdom-
inal infections may apply also to higher risk patients with
diverticulitis. Because infections in these patients are many
times characterized by the presence of difficult-to-treat
pathogens, such as resistant gram-negative bacteria, Entero-
coccus, and Candida, antimicrobial therapy may need to be
modified or extended.
Patient stratification
Most of the patients enrolled in trials of treatment for com-
plicated intra-abdominal infections have had community-
acquired infections, and have not been particularly compro-
mised thereby. Usually, these patients can be treated suc-
cessfully with an adequate source control procedure and an
appropriate antimicrobial regimen. However, certain pa-
tients clearly are at higher risk for an adverse outcome. Mul-
tivariable analyses have identified a number of risk factors
that predict treatment failure and death. The Acute Physiol-
ogy and Chronic Health Evaluation (APACHE) II score, a
measure of the degree of physiological derangement induced
by the disease process and of the patient’s pre-morbid char-
acteristics, consistently has been the best predictor of out-
come [33]. However, this and many other risk factors are not
under the control of the clinician.
Risk factors that portend infection with more resistant or
difficult-to-treat organisms are more likely to be relevant to
the selection of specific antimicrobial therapy. Patients likely
to harbor resistant pathogens are those with nosocomially
acquired intra-abdominal infections or who already have re-
ceived antimicrobial therapy. Patients who have recently un-
dergone a surgical procedure and or who reside in a long-
term care facility also are at risk of harboring resistant
organisms [68]. It has been hypothesized that such higher
risk patients should receive a broader-spectrum antimicro-
bial regimen [69]. Although this approach has not been tested
directly, a higher mortality rate has been found in seriously
ill patients with intra-abdominal infections treated with an
“inadequate” empiric regimen, “inadequate” being defined
as lacking activity against one or more of the microorgan-
isms isolated from definitive cultures [70].
Gram-negative coverage
The SIS and IDSA guidelines recommended use of
broader-spectrum gram-negative antimicrobial agents when
treating higher risk patients or those with more severe intra-
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abdominal infections. This approach could be applicable to
some patients with diverticulitis, particularly those in whom
initial antimicrobial therapy for their disease has failed. Such
patients might be suspected of having relatively resistant
gram-negative organisms as a result of prior antimicrobial
therapy.
Enterococcal coverage
Although Enterococcus spp. normally are part of the
colonic flora and are isolated from a certain percentage of
patients with complicated intra-abdominal infections, the
routine use of antimicrobial regimens that provide entero-
coccal coverage is not beneficial clinically [71]. However,
there are some patients for whom enterococcal coverage has
been advocated [19,33]; this recommendation is based pri-
marily on the observation that patients whose cultures re-
veal Enterococcus are at higher risk for an adverse outcome
[71]. Patients at risk for enterococcal infection include those
with postoperative intra-abdominal infection, those with 
recurrent gastrointestinal perforation, those with high
APACHE II scores, and those receiving immunosuppressive
medications [71]. In addition, it seems reasonable that pa-
tients with significant prior antibiotic exposure would be
more likely to have Enterococcus infections and should be
considered for routine empiric anti-enterococcal coverage
[72]. Among the regimens described previously, imipenem/
cilastatin, ampicillin/sulbactam, piperacillin/tazobactam,
and moxifloxacin provide reliable enterococcal coverage.
Vancomycin or ampicillin can be added when it is believed
to be necessary to provide additional enterococcal coverage.
Vancomycin-resistant enterococci are only rarely identified
in intra-abdominal infections, usually in the setting of ter-
tiary peritonitis and substantial prior antimicrobial exposure.
If this pathogen is cultured, linezolid or another antibiotic to
which the organism is sensitive can be added.
Fungal coverage
Antifungal therapy generally is not recommended for pa-
tients with community-acquired intra-abdominal infections,
a consideration that would apply to most patients with di-
verticulitis. Fungal peritonitis is encountered primarily in
patients whose infections developed while they were re-
ceiving broad-spectrum antibiotics [19]. As such, empiric an-
tifungal therapy could be considered in patients in whom a
long course of medical therapy has failed and who require
operative intervention. If not already given, antifungal ther-
apy should be initiated in these patients if peritoneal cul-
tures are positive for Candida [73]. Fluconazole is an appro-
priate agent for most patients with peritonitis caused by C.
albicans, although some authorities have suggested that
fungicidal agents such as echinocandins or amphotericin B
have better efficacy. For patients with infections attributed
to C. glabrata or C. krusei, which are resistant to standard
doses of fluconazole, either voriconazole or an echinocandin
can be used.
Duration of Therapy
For patients with complicated intra-abdominal infections,
an unanswered question is the optimal duration of anti-
microbial therapy. The current approach is for shorter
courses of therapy, especially in patients exhibiting a satis-
factory clinical response. For patients with complicated in-
tra-abdominal infections, treatment longer than five to seven
days usually is not recommended [19,33].
At present, practice patterns with regard to the duration
of antimicrobial therapy for diverticulitis remain highly vari-
able. An approach similar to that used for complicated in-
tra-abdominal infections would seem as appropriate as any
other. Antibiotic therapy could be limited to five to seven
days, as was recommended in the SIS and IDSA guidelines
for complicated intra-abdominal infections [19,33]. Another
option would be to stop antibiotics once the patient has de-
fervesced, abdominal pain has resolved, and leukocytosis
has improved [74]. Patients who do not respond to initial
antimicrobial therapy should be re-evaluated with imaging
studies to ensure there is no focus of infection necessitating
intervention to achieve adequate source control. Arbitrary
changes in the antibiotic regimen without a necessary source
control procedure cannot be expected to be successful ac-
cording to experience in patients with complicated intra-ab-
dominal infections.
No published evidence indicates that treatment duration
should be based on the extent of diverticulitis. It could be
argued that patients with Hinchey III or IV diverticulitis have
more extensive disease and therefore require longer antibi-
otic therapy. However, these patients usually are treated
through a source control procedure, and the duration of an-
tibiotic therapy should be the same as that recommended for
patients with complicated intra-abdominal infections. Para-
doxically, patients with Hinchey I diverticulitis could theo-
retically require longer treatment than those with Hinchey III
or IV disease because typically, they do not undergo a source
control procedure, which eliminates most of the infecting or-
ganisms. Thus, for patients with acute diverticulitis, it would
seem reasonable to employ either a fixed duration of five to
seven days of antimicrobial therapy or a clinically determined
duration based on resolution of symptoms and signs of in-
flammation, regardless of the extent of disease.
Oral Antimicrobial Therapy
Patients who are hospitalized for acute diverticulitis
should be given intravenous antibiotics initially, as oral ab-
sorption may be sporadic in the face of localized peritonitis.
However, patients who respond to intravenous therapy may
be candidates for oral therapy to facilitate hospital discharge
(Table 3). In addition, a large number of patients are treated
as outpatients with oral therapy alone.
A number of oral drugs are potentially useful as single
agents or in combination regimens for treating patients with
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aFood and Drug Administration approved for intra-abdominal 
infections.
bNot FDA approved for intra-abdominal infections.
cFDA approved for intra-abdominal infections when administered
with metronidazole.
diverticulitis. The best evidence for the efficacy of an oral
regimen comes from the study of Solomkin et al. [53], in
which a switch to the use of oral ciprofloxacin  metron-
idazole was found to be as effective as continued intravenous
therapy in the treatment of patients with complicated intra-
abdominal infections. In other trials for complicated intra-
abdominal infections, oral moxifloxacin was used as contin-
uation therapy after intravenous moxifloxacin [56], and
amoxicillin/clavulanic acid was used as continuation ther-
apy after piperacillin/tazobactam or a carbapenem [33]. No
prospective studies have investigated the use of oral antibi-
otics specifically for the treatment of diverticulitis.
In addition to ciprofloxacin, metronidazole, moxifloxacin,
and amoxicillin/clavulanic acid, oral formulations of
trimethoprim/sulfamethoxazole and clindamycin are avail-
able. Moxifloxacin and amoxicillin/clavulanic acid could be
used as monotherapy for outpatient management of diver-
ticulitis; the other agents would have to be combined to pro-
vide a regimen effective against both common gram-nega-
tive bacteria and anaerobes. The selection of a specific oral
regimen can be based on several factors, including cost and
convenience and the patient’s tolerance. In addition, if a pa-
tient’s condition improves on a given intravenous regimen,
it might be desirable to use that same regimen as continua-
tion oral therapy; however, this is applicable only to those
agents that have both oral and intravenous formulations. No
data indicate that switching to an oral regimen from another
class of drugs has any adverse impact on outcome in the in-
dividual patient.
Summary
This review was undertaken to investigate a few questions
regarding the use of antimicrobial agents in the management
of acute diverticulitis. Unfortunately, a review of the litera-
ture indicates that these questions must remain mostly unan-
swered, at least according to current principles of evidence-
based medicine.
(1) Among the many antibiotics available to treat this dis-
ease, is any single agent or combination regimen supe-
rior?
No regimen has demonstrated superiority. Certainly, car-
bapenems and piperacillin/tazobactam have the broadest
spectrum of activity, but there is no evidence that this trans-
lates into a clinical benefit. The use of some previously rec-
ommended agents, such as ampicillin/sulbactam and clin-
damycin, has been questioned because of changes in the
susceptibilities of the bacterial species commonly involved
in these infections. Other considerations in antibiotic selec-
tion are toxicity and ease of use. With regard to toxicity, in
the absence of a specific patient reaction to a given agent,
there seems little to differentiate most of the commonly used
antibiotics; however, aminoglycosides would be less desir-
able because of their toxicity. With regard to ease of use,
agents that can be given as monotherapy and can be ad-
ministered once daily would seem advantageous. In addi-
tion, easy conversion to oral therapy might be desirable.
Among the various agents, only fluoroquinolones offer the
advantage of conversion to oral therapy without having to
change the antibiotic. Finally, cost may be important, al-
though such data often are applicable only to a specific in-
stitution, and may vary according to specific insurance cov-
erage for individual patients undergoing outpatient therapy.
(2) What is the appropriate duration of antimicrobial ther-
apy when treating diverticulitis?
There is no clinical evidence with which to answer this
question properly. An approach similar to that employed for
complicated intra-abdominal infections—limiting antimicro-
bial therapy to five to seven days—seems reasonable. An-
other option is to determine duration of therapy on the ba-
sis of resolution of the symptoms and signs of the infection.
(3) When should antibiotic regimens be altered?
Again, there is little evidence to evaluate this issue specif-
ically. A reasonable approach is to re-evaluate the patient af-
ter five to seven days, or sooner if there are signs of clinical
deterioration. If initial management is deemed to have failed,
further evaluation should include imaging or other clinical
studies to determine whether the patient remains a candi-
date for nonoperative management or should undergo a
source control procedure. Clearly, a failure to provide ade-
quate source control, when needed, places the patient at high
risk for an adverse outcome, irrespective of any changes in
the antimicrobial regimen. For a patient receiving continued
nonoperative management, the potential risk of resistant
pathogens should be borne in mind when selecting further
antimicrobial therapy.
(4) What clinical conditions or patient risk factors (e.g., age
or disease severity) might prompt a change in the gen-
eral approach to the provision of antibiotics for this dis-
ease?
Certain patients are at higher risk for treatment failure be-
cause of co-morbid conditions and the severity of their sep-
tic complications. However, expanded antimicrobial therapy
probably is most important in those patients who are at risk
of harboring resistant pathogens. Patients who have had anti-
microbial therapy or who are likely for other reasons to be
colonized with resistant organisms may benefit from the se-
lective use of regimens with expanded gram-negative cover-
age, and possibly anti-enterococcal and antifungal activities.
Overall, given the paucity of data directly applicable to
antimicrobial therapy for diverticulitis, careful clinical stud-
ies to evaluate antibiotic regimens for this disease are war-
ranted. Until such data are available, we are forced to rely
on tradition, in vitro analyses, pharmacokinetic profiling,
and indirect evidence from studies of complicated intra-ab-
dominal infections to determine appropriate antimicrobial
therapy for patients with acute diverticulitis.
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